nmsg

Phase I data of RXDX-101, a kinase inhibitor discovered at Nerviano Medical Sciences, in patients with advanced solid tumors with relevant molecular alterations to be disclosed at 2014 ASCO

Nerviano, Italy, May 14, 2014 – Nerviano Medical Sciences has discovered RXDX-101, an oral pan-trk, ROS1, and ALK inhibitor, recently outlicenced to Ignyta, Inc, San Diego, CA.
Phase I results of RXDX-101 in patients with advanced solid tumors with relevant molecular alterations will be disclosed at the 2014 American Society of Clinical Oncology (ASCO) annual meeting.

 
Presentation title: Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
Authors: De Braud, F et al

Meeting: 2014 ASCO Annual Meeting
Abstract No: 2502

Sub-category: Cytotoxic and Other Novel Agents
Category: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

Type: Oral Abstract Session

Time: Saturday May 31, 1:15 PM to 4:15 PM Location: E Hall D2

Link to abstract on the conference website: http://abstracts.asco.org/144/AbstView_144_131059.html 
 

 

 

 

 

 

 

 

 

 
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.